Form 4 · Filed Mar 17, 2026, 12:00 PM UTC
TARS/Tarsus Pharmaceuticals, Inc.
Neervannan Seshadri — Chief Operating Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 15, 2026 | M | other | 26,287 | — | — | 97,104 |
| Mar 15, 2026 | M | other | 5,097 | $0 | — | 0 |
| Mar 15, 2026 | M | other | 8,148 | $0 | — | 8,148 |
| Mar 15, 2026 | M | other | 8,020 | $0 | — | 16,040 |
| Mar 15, 2026 | M | other | 5,022 | $0 | — | 15,067 |
Source: SEC EDGAR raw filing ↗ · Accession 0001827584-26-000007